Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya10971610.26442/00403660.2022.07.201744Research ArticleChronic kidney disease in outpatients with arterial hypertension: clinical characteristics and treatment efficacy (according to the national registry)OschepkovaElena V.aksenovaannav@gmail.comhttps://orcid.org/0000-0003-4534-9890AksenovaAnna V.aksenovaannav@gmail.comhttps://orcid.org/0000-0001-8048-4882OrlovskyAlexey А.aksenovaannav@gmail.comhttps://orcid.org/0000-0002-0794-4683ChazovaIrina E.aksenovaannav@gmail.comhttps://orcid.org/0000-0002-9822-4357Chazov National Medical Research Center of Cardiology120820229478108150908202209082022Copyright © 2022, Consilium Medicum2022<p><strong>А</strong><strong>im. </strong>To investigate the clinical characteristics and quality of treatment (according to the national guidelines) of patients with arterial hypertension (AH) and chronic kidney disease observed in primary health care.</p>
<p><strong>Materials and methods. </strong>The study was carried out on the basis of the AH registry data (<em>n=</em>43 133; 20052019 years). Glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula; renal structure and albuminuria were not evaluated. The analysis was performed using the SPSS software (version 22; SPSS Inc).</p>
<p><strong>Results. </strong>The creatinine level was assessed in 60% of patients, 23.6% of them had decreased eGFR60 ml/ min/1.73 m<sup>2</sup>. The incidence of co-morbid CVD and type 2 diabetes in patients with hypertension increased markedly with a decrease in eGFR (14 groups): the incidence of coronary artery disease increased 1.8 times (up to 72.5%), myocardial infarction 1.7 times (up to 20.6%), chronic heart failure 2 times (up to 84.0%), atrial fibrillation 10 times (up to 18.3%), history of stroke 3.7 times (up to 15.3%) and type 2 diabetes 2.4 times (up to 32.8%). Achievement of target goals of CV risk factors was not enough: systolic BP less than 50% of patients, triglycerides less than 7%, LDL-C in high and very high CVD risk patients less than 13%.</p>
<p><strong>Conclusion. </strong>Conducting timely assessment of renal function, drug therapy and lifestyle changes in patients with AH and decreased renal functional could prevent severe kidney damage, the development of CV complications, chronic renal failure and reduce mortality.</p>arterial hypertensionmyocardial infarctionacute coronary syndromeagerisk factorsblood pressuresmokingtype 2 diabetes mellitushyperlipidemiaarterial hypertension registryresistant arterial hypertensionартериальная гипертонияинфаркт миокардаострый коронарный синдромвозрастфакторы рискаартериальное давлениекурениесахарный диабет 2-го типагиперлипидемиярегистр артериальной гипертониирезистентная артериальная гипертония[Смирнов А.В., Шилов Е.М., Добронравов В.А., и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012;16(1):89-115 [Smirnov AV, Shilov EM, Dobronravov VA, et al. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Nefrologiia. 2012;16(1):89-115 (in Russian)]. DOI:10.24884/1561-6274-2012-16-1-89-115][Bidani AK, Griffin KA. Pathophysiology of Hypertensive Renal Damage. Hypertension. 2004;44(5):595-601. DOI:10.1161/01.HYP.0000145180.38707.84][Мясников А.Л. Гипертоническая болезнь. М.: Медгиз, 1954 [Miasnikov A.L. Gipertonicheskaia bolezn'. Moscow: Medgiz, 1954 (in Russian)].][Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019;74(1):120-31. DOI:10.1053/j.ajkd.2018.12.044][Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl. 1).][Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. In: Remuzzi G, ed. PLoS One. 2016;11(7):e0158765. DOI:10.1371/journal.pone.0158765][Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-52.][Ощепкова Е.В., Долгушева Ю.А., Жернакова Ю.В., и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпидемиологического исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19-24 [Oshchepkova EV, Dolgusheva IuA, Zhernakova IuV, et al. The prevalence of renal dysfunction in arterial hypertension (in the framework of the ESSE-RF study). Systemic Hypertension. 2015;12(3):19-24 (in Russian)].][Ощепкова Е.В., Довгалевский П.Я., Гриднев В.И., и др. Структура первичных элементов базы данных российского регистра больных артериальной гипертонией, ишемической болезнью сердца и хронической сердечной недостаточностью. Кардио-ИТ. 2014;1:0202 [Oshchepkova EV, Dovgalevsky PY, Gridnev VI, et al. Key data elements and definitions of the Russian registry of patients with arterial hypertension, coronary artery disease and chronic heart failure. Cardio-IT. 2014;1(2):0202 (in Russian)]. DOI:10.15275/cardioit.2014.0202][Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30. DOI:10.7326/0003-4819-158-11-201306040-00007][Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28. DOI:10.1038/ki.2010.483][Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YV. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. DOI:10.26442/2075082X.2019.1.190179][Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клинические рекомендации. 2021. Режим доступа: http://www.nephro.ru/content/files/standards/ckdru.pdf?ysclid=l5cj42wk1d714808532. Ссылка активна на 07.07.2022 [Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Klinicheskie rekomendatsii. 2021. Available at: http://www.nephro.ru/content/files/standards/ckdru.pdf?ysclid=l5cj42wk1d714808532. Accessed: 07.07.2022 (in Russian)].][Norton JM, Grunwald L, Banaag A, et al. CKD Prevalence in the Military Health System: Coded Versus Uncoded CKD. Kidney Med. 2021;3(4):586-95.e1. DOI:10.1016/j.xkme.2021.03.015][Keith DS, Nichols GA, Gullion CM, et al. Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. Arch Intern Med. 2004;164(6):659. DOI:10.1001/archinte.164.6.659][Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-87. DOI:10.1016/j.kint.2020.11.003][Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. DOI:10.1016/j.jacc.2018.11.003]